APA (7th ed.) Citation

Arzimanoglou, A., Ferreira, J. A., Satlin, A., Mendes, S., Williams, B., Critchley, D., . . . Bibbiani, F. (2016). Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: An interim analysis from a multicenter, randomized, active-controlled, open-label study. European journal of paediatric neurology, 20(3), 393-402. https://doi.org/10.1016/j.ejpn.2015.12.015

Chicago Style (17th ed.) Citation

Arzimanoglou, Alexis, et al. "Safety and Pharmacokinetic Profile of Rufinamide in Pediatric Patients Aged Less than 4 Years with Lennox-Gastaut Syndrome: An Interim Analysis from a Multicenter, Randomized, Active-controlled, Open-label Study." European Journal of Paediatric Neurology 20, no. 3 (2016): 393-402. https://doi.org/10.1016/j.ejpn.2015.12.015.

MLA (9th ed.) Citation

Arzimanoglou, Alexis, et al. "Safety and Pharmacokinetic Profile of Rufinamide in Pediatric Patients Aged Less than 4 Years with Lennox-Gastaut Syndrome: An Interim Analysis from a Multicenter, Randomized, Active-controlled, Open-label Study." European Journal of Paediatric Neurology, vol. 20, no. 3, 2016, pp. 393-402, https://doi.org/10.1016/j.ejpn.2015.12.015.